Revance Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

LOS ANGELES, Jan. 20, 2025 /PRNewswire/ — The Schall Law Firm, a firm dedicated to protecting shareholder rights, has announced a class action lawsuit against Revance Therapeutics, Inc. (“Revance” or “the Company”) RVNC for allegedly breaching sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 enforced by the U.S. Securities and Exchange Commission.

Investors who bought shares during the period from February 29, 2024 to December 6, 2024 (the “Class Period”) should reach out to the firm before March 4, 2025.

Shareholders who believe they have incurred losses can click here to find out how to participate in the case.

For more information, contact Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335. You can also visit their website at www.schallfirm.com, or email at bschall@schallfirm.com.

It is important to note that the class has not yet been certified. Until certification happens, you are not represented by an attorney. Chose to take no action, and you may remain an absent class member.

The Complaint alleges the Company made false and misleading statements to investors. Revance reportedly breached its distribution agreement with Teoxane SA, increasing the risk of litigation and reputational damage. Furthermore, these issues could delay or alter Revance’s tender offer from Crown Laboratories, Inc. Due to these concerns, the company’s statements were deemed false and deceptive throughout the entire class period, leading to significant losses for investors once the truth emerged.

Investors should consider joining the case to seek recovery for their losses.

The Schall Law Firm actively represents investors globally and focuses on securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in certain jurisdictions under applicable laws and ethical standards.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rvnc-investors-have-opportunity-to-lead-revance-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302355037.html

SOURCE The Schall Law Firm